The purpose of this study is to test an experimental drug called RMC-6236. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. RMC-6236 is currently being investigated in other ongoing studies in non-small cell lung cancer (NSCLC). If you consent and meet the study requirements, you will be randomly assigned to receive either RMC-6236 or docetaxel.

Join our study for a new treatment for a type of blood cancer, Acute Myeloid Leukemia (AML) with a specific mutation called FLT3. We are looking for older adults who have recently been diagnosed and who may not be fit for intense treatments. The study involves testing a combination of medicines to see if they help. This study looks at two ways to treat AML. We will compare the usual treatment with Azacitidine and Venetoclax to adding a new medicine called Gilteritinib to them.

The purpose of this study is to evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP for the treatment of the GCB subtype of DLBCL.

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and tolerability of giving a new drug called ABBV-453 alone and in combination with other antimyeloma drugs to patients with relapsed or refractory multiple myeloma.

Have you been diagnosed with stage II or III triple negative breast cancer (TNBC) and have residual disease after therapy, but haven't had surgery yet? If so, you may be able to take part in a research study examining how often cancer DNA in the blood (called ctDNA) can be used to detect minimal residual disease (MRD) and early signs of cancer returning after surgery. Some participants who test positive for ctDNA but show no signs of cancer on scans may receive a study drug called Dato-DXd if they qualify.

The purpose of this study is to learn how microbes in the uterus and gut (bacteria, viruses, fungi) and your own innate immune system (the first line of defense of the body) impacts how well certain treatments work for endometrial cancer. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Researchers are trying to find out if they can slow the growth of prostate cancer by adding green tea to patients treatment. Researchers are also trying to find out if this could be better or worse than usual care patients get.

We are doing a study to see if a new treatment, called INO-3107, can help people with recurrent respiratory papillomatosis (RRP). We want to find out if this treatment works well and if it helps patients need fewer surgeries in the future.